
Stay ahead in the competitive landscape with unparalleled access to the latest academic research and drug development landscape data.
Key Benefits
Competitive and Business Intelligence
Portfolio Strategy and Product Planning
Research and Development
Pharmaceutical Companies
Bio-tech Companies
Life Sciences Corporations
Venture Capital & Investment Firms
Contract Research Organizations (CROs)
Academic Institutions
Government & Regulatory Agencies
Generic & Biosimilar Companies
Research Labs
Contract Development & Manufacturing Organizations (CDMOs)
Consultancies & Agencies

Pharma Market Intelligence
AdisInsight APIs
AdisInsight APIs are a collection of APIs that help you retrieve information from the AdisInsight database. Each of our APIs can be seen as building blocks for data integration, data analysis, and insight extraction.
AdisInsight is Springer Nature's Pharma database for drug research and development, disease treatment and decision making, based on trusted, scientifically sound data. AdisInsight brings together essential scientific information on drugs in commercial development, key clinical trials, deals, patents and safety profiles, in one easy-to-use database.

Life Sciences & Pharma Research
Full Text API (TDM)
Springer Nature's Full Text API (TDM) offers access to a meticulously curated set of scholarly journals, and articles ensuring broad access to the latest research and insights.
Tap into this rich repository to fuel competitive research in drug discovery, molecular biology, clinical pharmacology, and biotechnology.
There is an ever-increasing amount of knowledge and data at our fingertips, ready to accelerate new discoveries. The key to unlocking this potential is tools that can select, read and analyze large quantities of text and data and provide the insights you need. At Springer Nature, we provide advanced data solution products to help advance your scientific discoveries and fast-track your innovations.
Return all the drugs being developed by Pfizer that are in clinical development for cancer in the USA utilizing a kinase inhibitor mechanism of action in a small molecule drug class that had an update in 2024.
{
"fromDate": "2024-01-01",
"toDate": "2024-12-31",
"organisations": [
"Pfizer"
],
"phases": [
"Phase III",
"Phase II",
"Phase I"
],
"locations": [
"U S A"
],
"indications": [
"Cancer"
],
"moas": [
"Phosphotransferase inhibitors"
],
"drugClass": [
"Small molecules"
],
"page": 1
}Access our latest TDM Use Case
How Benevolent AI uses Springer Nature’s journal content and TDM API to assist its artificial intelligence assisted drug discovery process.
White Paper
Bringing Insight to Data: Info Pros’ Role in Text and Data Mining (PDF, 505.29 KB).